Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of OCT461201 in Healthy Volunteers
NCT06398925Phase 1Completed
- Sponsor
- Oxford Cannabinoid Technologies
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OCT461201 in chemotherapy-induced peripheral neuropathy (CIPN) and irritable bowel syndrome (IBS) (5 arms), sponsored by Oxford Cannabinoid Technologies. Primary endpoint: Treatment Emergent Adverse Events. Started Jul 2023; status: completed.
02
Drugs
OCT461201
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06398925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06398925.